companiesCompany
Replimune
Oncolytic virus company whose RP1 (Tudriqev) was approved in August 2026 after an initial FDA rejection.
Vusolimogene oderparepvec (RP1), RP2 (anti-CTLA-4-expressing, uveal melanoma).
Pages like this
not linked directly; found by shared links- PairingOncolytic virus + PD-1 blockade
Shares Vusolimogene oderparepvec, Oncolytic viruses, Melanoma.
- PersonKevin Harrington
Shares Vusolimogene oderparepvec, Oncolytic viruses that make interleukin-12 only inside the tumour, Oncolytic viruses, Melanoma.
- ProductTalimogene laherparepvec
Shares Oncolytic viruses that make interleukin-12 only inside the tumour, Oncolytic viruses, Melanoma.
- PersonIgor Puzanov
Shares Oncolytic viruses, Melanoma.
- ProductCretostimogene grenadenorepvec
Shares Oncolytic viruses that make interleukin-12 only inside the tumour, Oncolytic viruses.
- InstitutionUniversity of Arizona Cancer Center
- TechnologyIntratumoural gene electrotransfer (IL-12 plasmid)
Shares Oncolytic viruses, Melanoma.
- ProductADU-S100 (MIW815)
Shares Cold tumours and the immunosuppressive microenvironment, Melanoma.